JP2004529874A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529874A5
JP2004529874A5 JP2002563877A JP2002563877A JP2004529874A5 JP 2004529874 A5 JP2004529874 A5 JP 2004529874A5 JP 2002563877 A JP2002563877 A JP 2002563877A JP 2002563877 A JP2002563877 A JP 2002563877A JP 2004529874 A5 JP2004529874 A5 JP 2004529874A5
Authority
JP
Japan
Prior art keywords
ring
hydrogen bond
hydrophobic group
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002563877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529874A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/000447 external-priority patent/WO2002064080A2/en
Publication of JP2004529874A publication Critical patent/JP2004529874A/ja
Publication of JP2004529874A5 publication Critical patent/JP2004529874A5/ja
Abandoned legal-status Critical Current

Links

JP2002563877A 2001-02-14 2002-02-13 マトリックスメタロプロテイナーゼ阻害剤 Abandoned JP2004529874A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26882101P 2001-02-14 2001-02-14
PCT/IB2002/000447 WO2002064080A2 (en) 2001-02-14 2002-02-13 Matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004529874A JP2004529874A (ja) 2004-09-30
JP2004529874A5 true JP2004529874A5 (enExample) 2005-07-21

Family

ID=23024626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563877A Abandoned JP2004529874A (ja) 2001-02-14 2002-02-13 マトリックスメタロプロテイナーゼ阻害剤

Country Status (14)

Country Link
US (2) US20030078276A1 (enExample)
EP (1) EP1361873A4 (enExample)
JP (1) JP2004529874A (enExample)
AR (1) AR033859A1 (enExample)
AU (1) AU2002228302A1 (enExample)
BR (1) BR0207864A (enExample)
CA (1) CA2437643A1 (enExample)
HN (1) HN2002000037A (enExample)
MX (1) MXPA03007250A (enExample)
PA (1) PA8539301A1 (enExample)
PE (1) PE20020873A1 (enExample)
SV (1) SV2002000874A (enExample)
UY (1) UY27174A1 (enExample)
WO (1) WO2002064080A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
DOP2002000328A (es) 2001-02-14 2003-08-30 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
BR0207865A (pt) 2001-02-14 2004-03-23 Warner Lambert Co Benzotiadiazinas inibidores de metaloproteinases de matriz
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PE20030541A1 (es) * 2001-10-12 2003-08-13 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
AU2002249275A1 (en) * 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2002331362A1 (en) * 2002-07-12 2004-02-02 Warner-Lambert Company Llc New alkynylated quinazolin compounds as mmp-13 inhibitors
CA2492391A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
MXPA05000476A (es) * 2002-07-17 2005-03-23 Warner Lambert Co Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib.
EP1536786A1 (en) * 2002-07-17 2005-06-08 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003281169A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003281168A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
BR0313385A (pt) * 2002-08-13 2005-06-14 Warner Lambert Co Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1539709A1 (en) 2002-08-13 2005-06-15 Warner-Lambert Company LLC Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
MXPA05001784A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de isoquinolina como inhibidores de metaloproteinasa de matriz.
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
US7166609B2 (en) 2002-11-02 2007-01-23 Sanofi-Aventis Deutschland Gmbh Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
EP1680125A1 (en) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
EP1657238A4 (en) * 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
CA2545855A1 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
CA2559062A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
CN101094829B (zh) * 2004-12-07 2012-02-08 富山化学工业株式会社 新的氨茴酸衍生物或其盐
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
US8293754B2 (en) 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
AU2006306991A1 (en) * 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2685753A1 (en) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
EP2240178A4 (en) * 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
EP2303862B1 (en) 2008-05-27 2016-08-24 The Board of Regents of The University of Texas System Wnt protein signalling inhibitors
JP5657201B2 (ja) * 2008-09-30 2015-01-21 サンメディカル株式会社 酵素阻害作用または酵素阻害作用と抗菌作用とを有する歯科用組成物
CN102627657B (zh) * 2012-03-09 2015-01-07 苏州施亚生物科技有限公司 3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法
CN103012189A (zh) * 2012-12-20 2013-04-03 天津理工大学 具有抗血小板聚集作用的酰胺类化合物及其制备和应用
MX2016004250A (es) * 2013-10-07 2016-07-12 Bayer Pharma AG Tienouracilcarboxamidas ciclicas y usos de las mismas.
EP3299371B1 (en) * 2015-05-20 2021-08-25 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and use thereof
WO2016184313A1 (zh) 2015-05-20 2016-11-24 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
CN109593066B (zh) * 2018-12-21 2020-06-19 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
US11919895B2 (en) * 2019-10-25 2024-03-05 Saint Louis University GPR183 antagonists for the treatment of pain
CN115197225B (zh) * 2021-09-03 2023-04-11 贵州大学 一种五元杂环并喹唑啉酮类化合物及其制备方法
CN113773277B (zh) * 2021-09-18 2023-12-05 兰州大学 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172A (en) * 1845-09-02 Coal-breaker
US161000A (en) * 1875-03-23 Improvement in millstone-bushes
US130278A (en) * 1872-08-06 Improvement in pipe-tongs
US156061A (en) * 1874-10-20 Improvement in boot and shoe nails
US193377A (en) * 1877-07-24 Improvement in bee-hives
US144274A (en) * 1873-11-04 Improvement in self-closing telegraph-keys
US151555A (en) * 1874-06-02 Improvement in street-railway switches
US156069A (en) * 1874-10-20 Improvement in lithographic printing-presses
US129672A (en) * 1872-07-23 Improvement in heating-stoves
US151558A (en) * 1874-06-02 Improvement in the modes of machine-sewing
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
WO1998025597A2 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
BR0207865A (pt) * 2001-02-14 2004-03-23 Warner Lambert Co Benzotiadiazinas inibidores de metaloproteinases de matriz

Similar Documents

Publication Publication Date Title
JP2004529874A5 (enExample)
Küçükgüzel et al. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide
TW309512B (enExample)
JP5468007B2 (ja) 新規なプロスタグランジンi2誘導体
JP2008505117A5 (enExample)
JP2005532287A5 (enExample)
CY1108996T1 (el) Παραγωγα ινδολ-3-καρβονυλο-σπειρο-πιπεριδινης ως ανταγωνιστες του v1a υποδοχεα
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
EA200500096A1 (ru) Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ
ATE386014T1 (de) Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung
JP2010501478A5 (enExample)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
JP2005514457A5 (enExample)
Han et al. Discovery of potent and selective CDK8 inhibitors through FBDD approach
JP2002543114A5 (enExample)
Liu et al. Design, synthesis, and biological evaluation of new 1, 2, 3-triazolo-2′-deoxy-2′-fluoro-4′-azido nucleoside derivatives as potent anti-HBV agents
JP6850361B2 (ja) キナーゼを選択的に阻害する化合物及びその使用
CN109053854A (zh) 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
JPS6360755B2 (enExample)
JP2008545718A5 (enExample)
Wucherer-Plietker et al. Discovery of novel 7-azaindoles as PDK1 inhibitors
JP2008069182A5 (enExample)
JP2005511594A5 (enExample)
Zheng et al. Pyridopyrimidine analogues as novel adenosine kinase inhibitors